Last week was the high water mark for earning reports from China life science companies. WuXi PharmaTech saw a very solid 80% increase in revenues and 134% jump in net income, though questions remain about its AppTec acqusition; American Oriental Bioengineering announced a huge acquisition and higher revenues; Sinovac Biotech enjoyed a substantial increase in Q2 revenues helped by a one-time purchase for earthquake victims; China Sky One Medical detailed excellent Q2 performance and the projects that will keep the company on a growth path; BMP Sunstone reported a very positive Q2 thanks to the Sunstone acquisition; 3SBio Inc. said revenues rose but net income fell; the revenues for Benda Pharmaceutical’s gene-therapy cancer drug slipped though overall revenues were higher; Tongjitang Chinese Medicines  continues to be hurt by counterfeit versions of its flagship product; China Medical Technologies placed $240 million in 4% convertible senior notes, together with an unusual shorting stratagem; China Sky One Medical developed a nasal spray for rheumatic disease; and Schering-Plough  bought in the 45% of its majority-owned China JV that it did not already own.  More details... 

Stock Symbols: (NYSE: WX) (NYSE: AOB) (AMEX: SVA) (AMEX: CSY) (NSDQ: BJGP) (NSDQ SSRX) (OTCBB: BPMA) (NYSE: TCM) (NSDQ: CMED) (NYSE SGP)

Benda Pharmaceutical, Inc., which produces the gene-therapy cancer drug Gendicine® along with TCM products and conventional pharmaceuticals, reported that Q2 revenues climbed 40% to $7.3 million. Nevertheless, the company still suffered a loss of $1.8 million in the quarter, though that loss was a significant improvement over the $8.8 million that Benda lost in the year-earlier quarter. The results from the company’s SiBiono subsidiary, which produces Gendicine, were not as positive. Revenues dropped 47% in the period to $800,000. More details...

Stock Symbol: (OTCBB: BPMA)

Benda Pharmaceutical (OTCBB: BPMA) announced that it has begun to explore strategic alternatives, having signed up CRT Capital Group LLC to assist the company. They will explore M&A, joint venture, divestiture, spin-off, financing or other capital market transactions. Benda announced at the same time that it would seek to move its listing to the American Exchange. Benda has good reason to seek an AMEX listing. More details...

Stock Symbols: (OTCBB: BPMA) (NYSE: AOB)

During the past week, ChinaBio® Today published articles that ran along two major themes: broad overviews of China biotech and progress reports from individual companies. On the broad overview front, Dr. Charles C. Liu, a guest author, discussed proposed changes in China patent law, and eight researchers wrote a detailed analysis of biotech in China, while recommending changes that will improve growth.  Among the individual companies reporting milestones, Unigene will establish a $30 million manufacturing joint venture in China; Sinobiomed received a 9 million RMB ($1.24 million) grant to conduct a Phase II trial of its malaria vaccine; Biosensors will complete its acquisition of the remaining 50% of fellow stent company JW Medical Systems Ltd; Calypte received GMP approval of its China manufacturing facility for its HIV diagnostic test; and Benda announced expanded manufacturing capability.  More details....

Stock Symbols: (OTCBB: SOBM) (SGX: B20) (OTCBB: CBMC) (OTCBB: BPMA)

Benda Pharmaceutical announced that its newly expanded Ebei manufacturing facility has begun production, raising the company’s ability to increase its revenues. In November, one of five new production lines received Good Manufacturing Practices (GMP) certification. The line, which produces tablets, has the ability to manufacture $1.8 million worth of product. Production began in December. More details...

Stock Symbol: (OTCBB: BPMA)

Last week, WuXi PharmaTech reported a very solid 80% increase in revenues and 134% jump in net income, though questions remain about its AppTec acqusition; American Oriental Bioengineering announced a huge acquisition and higher revenues; Sinovac Biotech enjoyed a substantial increase in Q2 revenues helped by a one-time purchase for earthquake victims; China Sky One Medical detailed excellent Q2 performance and the projects that will keep the company on a growth path; BMP Sunstone reported a very positive Q2 thanks to the Sunstone acquisition; 3SBio Inc. said revenues rose but net income fell; the revenues for Benda Pharmaceutical’s gene-therapy cancer drug slipped though overall revenues were higher; Tongjitang Chinese Medicines  continues to be hurt by counterfeit versions of its flagship product; China Medical Technologies placed $240 million in 4% convertible senior notes, together with an unusual shorting stratagem; China Sky[More...]

Benda Pharmaceutical Capitalizes on Accelerated Healthcare Spending in China and Growing Opportunities for GendicineR Cancer Treatment

Benda Pharmaceutical, Inc. ( OTCBB: BPMA), a China-based pharmaceutical company producing both GendicineR, the world's first commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, announced today that it has launched a new investor video (www.bendapharma.com/video) to provide investors easy, quick and informative insight into the Benda and GendicineR investment opportunity.

Benda Pharmaceutical, Inc. ( OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as GendicineR, the world's first commercialized gene therapy medicine for the treatment of cancer, announced today that its Ebei plant received Good Manufacturing Practices (GMP) certification for its new tablets product line on November 26, 2007

Benda Pharmaceutical, Inc. ( OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as GendicineR, the world's first commercialized gene therapy medicine for the treatment of cancer, announced today that it has already recognized $1.3 MM in revenue from the previously reported $3.8 MM in combined GendicineR orders generated at China's recent national biotechnology conference.

Benda Pharmaceutical, Inc. ( OTCBB: BPMA), audio interview with Director & CFO Eric Yu